早期非小细胞肺癌立体定向消融放疗后的生存分析:单机构队列研究
本研究回顾性分析2018至2020年连续172例接受SABR的医学上无法手术的早期非小细胞肺癌患者,中位OS为35.3个月。多因素分析显示男性(HR 1.51,95% CI 1.01-2.28;p=0.05)和AACCI>5(HR 1.56,95% CI 1.06-2.31;p=0.026)是OS的显著负性预后因素,AACCI>5的显著效应仅在3年后显现(3年OS 37% vs 56%,p=0.021),1年OS相似(83% vs 86%,p=0.58)。作者结论认为精确影像引导的SABR对体能状态合理的医学上无法手术患者可行,早期死亡罕见。
要点
- 中位OS为35.3个月,男性(HR 1.51)和AACCI>5(HR 1.56)是OS显著负性预后因素。
- AACCI>5的OS显著效应仅在3年后显现(3年OS 37% vs 56%,p=0.021),1年OS相似(83% vs 86%,p=0.58)。
- 作者结论认为精确影像引导的SABR对体能状态合理的医学上无法手术ES-NSCLC患者可行,早期死亡罕见。
核心结论
- 作者结论认为精确影像引导的SABR对体能状态合理的医学上无法手术早期非小细胞肺癌患者可行,早期死亡在本真实世界队列中罕见,OS明显高于最佳支持治疗后的预期。
研究设计与样本
- 单机构回顾性队列研究,2010年8月至2022年共617例医学上无法手术的外周或中央型早期非小细胞肺癌患者接受SABR,本文回顾性分析其中2018至2020年连续172例的数据以分析总生存预后因素。
主要发现
- 中位OS为35.3个月。
- 单因素分析未发现OS与通气参数、组织学、PET或肿瘤中心位置相关。
- 多因素模型显示男性(HR 1.51,95% CI 1.01-2.28;p=0.05)和AACCI>5(HR 1.56,95% CI 1.06-2.31;p=0.026)是OS的显著负性预后因素。
- AACCI>5的显著效应仅在3年后显现(3年OS 37% vs 56%,p=0.021),1年OS相似(83% vs 86%,p=0.58)。
关键数值与推荐
- 所有患者生物有效剂量>100 Gy10;肿瘤直径<1 cm时,GTV+3 mm margin接受60 Gy分3-5次;30-33 Gy单次照射。
- 96%病例采用实时肿瘤追踪,4%采用内靶区方法。
- 单因素分析中肿瘤直径、生物有效剂量、性别和AACCI达到纳入多因素分析的标准。
临床怎么用
- 作者结论认为精确影像引导的SABR对体能状态合理的医学上无法手术早期非小细胞肺癌患者可行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small cell lung cancer (ES-NSCLC), but which patients benefit from stereotactic radiotherapy is unclear. The aim of this study was to analyze prognostic factors for early mortality. METHODS: From August 2010 to 2022, 617 patients with medically inoperable, peripheral or central ES-NSCLC were treated with SABR at our institution. We retrospectively evaluated the data from 172 consecutive patients treated from 2018 to 2020 to analyze the prognostic factors associated with overall survival (OS). The biological effective dose was > 100 Gy10 in all patients, and 60 Gy was applied in 3-5 fractions for a gross tumor volume (GTV) + 3 mm margin when the tumor diameter was < 1 cm; 30-33 Gy was delivered in one fraction. Real-time tumor tracking or an internal target volume approach was applied in 96% and 4% of cases, respectively. In uni- and multivariate analysis, a Cox model was used for the following variables: ventilation parameter FEV1, histology, age, T stage, central vs. peripheral site, gender, pretreatment PET, biologically effective dose (BED), and age-adjusted Charlson comorbidity index (AACCI). RESULTS: The median OS was 35.3 months. In univariate analysis, no correlation was found between OS and ventilation parameters, histology, PET, or centrality. Tumor diameter, biological effective dose, gender, and AACCI met the criteria for inclusion in the multivariate analysis. The multivariate model showed that males (HR 1.51, 95% CI 1.01-2.28; p = 0.05) and AACCI > 5 (HR 1.56, 95% CI 1.06-2.31; p = 0.026) were significant negative prognostic factors of OS. However, the analysis of OS showed that the significant effect of AACCI > 5 was achieved only after 3 years (3-year OS 37% vs. 56%, p = 0.021), whereas the OS in one year was similar (1-year OS 83% vs. 86%, p = 0.58). CONCLUSION: SABR of ES-NSCLC with precise image guidance is feasible for all medically inoperable patients with reasonable performance status. Early deaths were rare in our real-life cohort, and OS is clearly higher than would have been expected after best supportive care.
引用
- Resova K, Knybel L, Parackova T, et al. Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study. Radiat Oncol. 2024. PMID: 38637844. doi:10.1186/s13014-024-02439-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。